Taxotere cases filed in United States federal courts have been consolidated before Judge Kurt D. Engelhardt in the United States District Court for the Eastern District of Louisiana. The cases are part of multidistrict litigation (MDL) as ordered by the Judicial Panel on Multidistrict Litigation. Multidistrict litigation is a consolidation of civil cases transferred from different jurisdictions around the country to a single United States District Court to achieve certain pre-trial efficiencies. The aim of this consolidation is to preserve judicial resources, eliminate duplicities in the fact-finding process, and prevent inconsistencies in pre-trial rulings.
In April 2017, Judge Engelhardt entered a pretrial order allowing Plaintiffs to file their lawsuits directly in the MDL, which should help to make the filing process more efficient. As of April 17, 2017, there were 949 Taxotere lawsuits pending in the MDL Court.
Taxotere (docetaxel) is a chemotherapy drug approved in the treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer. It is administered intravenously, and is a member of a family of drugs called taxanes. It is used to try to prevent cancer cells from growing and dividing.
When Sanofi-Aventis started manufacturing Taxotere, it marketed and promoted it as more potent and effective than Taxol, a competing chemotherapy agent distributed and produced by Bristol-Myers Squibb. Sanofi-Aventis intentionally developed Taxotere to be twice as strong as Taxol in an effort to claim a large market share in the highly profitable chemotherapy market segment. However, Taxotere has been found to be significantly more dangerous and linked to a higher number of side effects as compared to Taxol. Additionally, Taxol can be used at lower doses than Taxotere with similar effects.
In 2007, Sanofi-Aventis issued a press release touting the efficacy of Taxotere based on a clinical study, GEICAM 9805. However, Sanofi-Aventis failed to inform the U.S. Food and Drug Administration (FDA), health care providers, and the public that in the GEICAM 9805 study permanent hair loss persisted into the follow-up period (10 years and five months was the median follow-up) and was observed to be ongoing in 9.2 percent of the patients taking Taxotere.
Hair loss during chemotherapy is expected. It is a very common side effect of fighting cancer. However, patients undergoing chemotherapy with Taxotere were not warned they could potentially experience permanent hair loss. Permanent hair loss is an extremely debilitating condition, especially for women. The permanent loss of hair is more than cosmetic. For cancer survivors it is a constant reminder of their struggle and a completely unnecessary result of chemotherapy treatment.
Lawyers at Beasley Allen continue to investigate, review and file cases involving women that have suffered permanent hair loss following chemotherapy with Taxotere. For more information, contact Beau Darley, Melissa Prickett, or Liz Eiland lawyers in the firm’s Mass Torts Section, at 800-898-2034 or by email at Beau.Darley@beasleyallen.com, Melissa.Prickett@beasleyallen.com or Liz.Eiland@beasleyallen.com.
Sources: Pretrial Order No. 37, In re: Taxotere (Docetaxel) Prods. Liab. Litig., MDL No. 2740 (E.D. La. Apr. 6, 2017). and PR News Wire
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.